Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis

• At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health.
   
• At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36.
   
• Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.
   
• EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis.

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").